trending Market Intelligence /marketintelligence/en/news-insights/trending/w8um7vzhx0kvgjf-pbw1ig2 content esgSubNav
In This List

UK's GlaxoSmithKline to drop manufacturing operations in Bangladesh

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


UK's GlaxoSmithKline to drop manufacturing operations in Bangladesh

British pharmaceutical company GlaxoSmithKline PLC is shutting down its manufacturing operations in Bangladesh by the end of 2018, Reuters reported, citing a statement from Nakibur Rahman, the unit's managing director.

GSK Bangladesh Ltd.'s board decided to shut down the drugmaking factory but opted to keep the consumer healthcare business, which produces nutritional drink Horlicks, Sensodyne toothpaste and mouthwash, and energy drink Glaxose-D.

About 1,000 employees are expected to be affected if the decision, which is still pending shareholder approval, pushes through. The state-run Investment Corp. of Bangladesh holds 12% stake in the company, with 6% held by public and different institutions.